SEC Form 3 · accession 0002153366-26-000004
Electra Therapeutics, Inc. · ETRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Graham Parry
Officer — Chief Scientific Officer
Period of report
Sep 18, 2026
Accepted (ET)
Sep 18, 2026 · 4:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0002088082
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $4.40 | holding | — | — | — | — | Nov 16, 2033 | Common Stock | 101,147 | — | D |
| Employee Stock Option (right to buy)F2 | $4.96 | holding | — | — | — | — | Feb 12, 2036 | Common Stock | 219,562 | — | D |
| Employee Stock Option (right to buy)F3 | $15.00 | holding | — | — | — | — | Sep 16, 2036 | Common Stock | 155,979 | — | D |
| Employee Stock Option (right to buy)F4 | $15.00 | holding | — | — | — | — | Sep 16, 2036 | Common Stock | 46,122 | — | D |
| Employee Stock Option (right to buy)F5 | $15.00 | holding | — | — | — | — | Sep 16, 2036 | Common Stock | 4,193 | — | D |
| Series A Convertible Preferred StockF6,F7 | — | holding | — | — | — | — | — | Common Stock | 85,504 | — | D |
Explanation of responses
- F11/4th of the total shares subject to this option vested one year after January 1, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
- F21/48th of the total shares subject to this option shall vest monthly after January 1, 2026. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
- F31/48th of the total shares subject to this option shall vest monthly commencing from September 17, 2026.
- F4The shares subject to this option are fully vested upon the date of grant.
- F51/4th of the total shares subject to this option shall vest monthly commencing on September 2, 2026.
- F6Each share of Series A Convertible Preferred Stock (the "Preferred Stock") will automatically convert into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
- F77,125 of the shares ("Restricted Shares") shall be subject to vesting as follows: 1/4th of the Restricted Shares shall vest monthly commencing from September 2, 2026.